Abstract

Journal of Alzheimer’s Disease, vol. 91, no. 3, 2023, pp. 915-922, DOI: 10.3233/JAD-221065
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad221065
On page 917, in the section “CASE PRESENTATION”, paragraph 4, line 4, the Aβ42/40 ratio (0.06) was miswritten as follows:
“CSF biomarkers were suggestive of AD, with an increased p-tau181 concentration (51.57 pg/ml, 80.39 pg/ml; normal: 19.66–45.67 pg/ml) and a decreased Aβ42/40 ratio (0.06, 0.08; normal: 0.10), and increased t-tau levels in two tests (446.14 pg/ml, 425.91 pg/ml; normal: 47.00–225.00 pg/ml).”
The Aβ42/40 ratio should be 0.088 and 0.082 (this time we keep three decimal places) as shown in the below (the rest results remain the same):
“CSF biomarkers were suggestive of AD, with an increased p-tau181 concentration (51.57 pg/ml, 80.39 pg/ml; normal: 19.66–45.67 pg/ml) and a decreased Aβ42/40 ratio (0.088, 0.082; normal:>0.10), and increased t-tau levels in two tests (446.14 pg/ml, 425.91 pg/ml; normal: 47.00–225.00 pg/ml).”
Aβ42/40 ratio in 2020 was also miswritten in Table 1 on page 919. We modified 0.06 and 0.08 as 0.088 and 0.082 (the rest remain unchanged) in revised Table 1 in the below. The corrected Aβ42/40 ratio is less than 0.10 (cut-off value), which still supports the diagnosis.
Summary of the AD-related tests
MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; WHO-UCLA AVLT, World Health Organization-University of California-Los Angeles Auditory Verbal Learning Test; CDR, Clinical Dementia Rating; WMS-IV, Wechsler Memory Scale Fourth Edition; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography; FDG, 18-F fluorodeoxyglucose; [11C]PiB, [11C] Pittsburgh compound B; 18F-PM-PBB3, [18F]PM-pyridinyl-butadienyl-benzothiazole 3 (PBB3); MRA, magnetic resonance angiography.
